ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
Balaxi Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report forms part of the company's Annual Report.
Balaxi Pharmaceuticals Limited will hold its 83rd Annual General Meeting on August 24, 2026. The meeting will be conducted via video conferencing to transact ordinary and special business.
Balaxi Pharmaceuticals will hold a board meeting on August 5, 2026, to consider and approve its unaudited standalone and consolidated financial results for the June 2026 quarter.
Balaxi Pharmaceuticals clarified reporting discrepancies in its March 2026 financial results. The company filed revised XBRL results to correct inadvertent errors in expense and income figures.
Balaxi's FY26 was a transformational year focused on backward integration. Despite a 7.7% revenue decline to ₹270.17 Cr due to working capital issues in Angola, gross margins improved to 44.2%.
Balaxi Pharmaceuticals re-appointed Akshita Ostwal as Independent Director for a five-year term. The board also re-appointed Siva Rama Krishna & Associates as Internal Auditors.
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹70.7 Cr (-7.3% YoY) and net profit of ₹0.6 Cr (-93.0% YoY) for Q4 FY26.
Balaxi Pharmaceuticals approved audited FY26 financial results and recommended re-appointing Ms. Akshita Ostwal as Independent Director. The company also received a manufacturing license for its new plant.
Balaxi Pharmaceuticals scheduled a board meeting on May 28, 2026, to approve audited FY2026 financial results. Trading window remains closed until May 30, 2026.
Balaxi Pharmaceuticals Limited clarified to the NSE that the recent significant movement in its share price is purely market-driven. The company confirmed there is no undisclosed material information or announcement that could impact price or volume behaviour, maintaining compliance with SEBI LODR regulations.
Balaxi Pharmaceuticals Ltd reported net profit of ₹0.3 Cr (-94.4% YoY) for Q3 FY26.